Cargando…
A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase
Since 2000, some thirteen quinolones and fluoroquinolones have been developed and have come to market. The quinolones, one of the most successful classes of antibacterial drugs, stabilize DNA cleavage complexes with DNA gyrase and topoisomerase IV (topo IV), the two bacterial type IIA topoisomerases...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865888/ https://www.ncbi.nlm.nih.gov/pubmed/36675148 http://dx.doi.org/10.3390/ijms24021634 |
_version_ | 1784875951500296192 |
---|---|
author | Morgan, Harry Lipka-Lloyd, Magdalena Warren, Anna J. Hughes, Naomi Holmes, John Burton, Nicolas P. Mahenthiralingam, Eshwar Bax, Ben D. |
author_facet | Morgan, Harry Lipka-Lloyd, Magdalena Warren, Anna J. Hughes, Naomi Holmes, John Burton, Nicolas P. Mahenthiralingam, Eshwar Bax, Ben D. |
author_sort | Morgan, Harry |
collection | PubMed |
description | Since 2000, some thirteen quinolones and fluoroquinolones have been developed and have come to market. The quinolones, one of the most successful classes of antibacterial drugs, stabilize DNA cleavage complexes with DNA gyrase and topoisomerase IV (topo IV), the two bacterial type IIA topoisomerases. The dual targeting of gyrase and topo IV helps decrease the likelihood of resistance developing. Here, we report on a 2.8 Å X-ray crystal structure, which shows that zoliflodacin, a spiropyrimidinetrione antibiotic, binds in the same DNA cleavage site(s) as quinolones, sterically blocking DNA religation. The structure shows that zoliflodacin interacts with highly conserved residues on GyrB (and does not use the quinolone water–metal ion bridge to GyrA), suggesting it may be more difficult for bacteria to develop target mediated resistance. We show that zoliflodacin has an MIC of 4 µg/mL against Acinetobacter baumannii (A. baumannii), an improvement of four-fold over its progenitor QPT-1. The current phase III clinical trial of zoliflodacin for gonorrhea is due to be read out in 2023. Zoliflodacin, together with the unrelated novel bacterial topoisomerase inhibitor gepotidacin, is likely to become the first entirely novel chemical entities approved against Gram-negative bacteria in the 21st century. Zoliflodacin may also become the progenitor of a new safer class of antibacterial drugs against other problematic Gram-negative bacteria. |
format | Online Article Text |
id | pubmed-9865888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98658882023-01-22 A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase Morgan, Harry Lipka-Lloyd, Magdalena Warren, Anna J. Hughes, Naomi Holmes, John Burton, Nicolas P. Mahenthiralingam, Eshwar Bax, Ben D. Int J Mol Sci Article Since 2000, some thirteen quinolones and fluoroquinolones have been developed and have come to market. The quinolones, one of the most successful classes of antibacterial drugs, stabilize DNA cleavage complexes with DNA gyrase and topoisomerase IV (topo IV), the two bacterial type IIA topoisomerases. The dual targeting of gyrase and topo IV helps decrease the likelihood of resistance developing. Here, we report on a 2.8 Å X-ray crystal structure, which shows that zoliflodacin, a spiropyrimidinetrione antibiotic, binds in the same DNA cleavage site(s) as quinolones, sterically blocking DNA religation. The structure shows that zoliflodacin interacts with highly conserved residues on GyrB (and does not use the quinolone water–metal ion bridge to GyrA), suggesting it may be more difficult for bacteria to develop target mediated resistance. We show that zoliflodacin has an MIC of 4 µg/mL against Acinetobacter baumannii (A. baumannii), an improvement of four-fold over its progenitor QPT-1. The current phase III clinical trial of zoliflodacin for gonorrhea is due to be read out in 2023. Zoliflodacin, together with the unrelated novel bacterial topoisomerase inhibitor gepotidacin, is likely to become the first entirely novel chemical entities approved against Gram-negative bacteria in the 21st century. Zoliflodacin may also become the progenitor of a new safer class of antibacterial drugs against other problematic Gram-negative bacteria. MDPI 2023-01-13 /pmc/articles/PMC9865888/ /pubmed/36675148 http://dx.doi.org/10.3390/ijms24021634 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Morgan, Harry Lipka-Lloyd, Magdalena Warren, Anna J. Hughes, Naomi Holmes, John Burton, Nicolas P. Mahenthiralingam, Eshwar Bax, Ben D. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title | A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title_full | A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title_fullStr | A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title_full_unstemmed | A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title_short | A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase |
title_sort | 2.8 å structure of zoliflodacin in a dna cleavage complex with staphylococcus aureus dna gyrase |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865888/ https://www.ncbi.nlm.nih.gov/pubmed/36675148 http://dx.doi.org/10.3390/ijms24021634 |
work_keys_str_mv | AT morganharry a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT lipkalloydmagdalena a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT warrenannaj a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT hughesnaomi a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT holmesjohn a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT burtonnicolasp a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT mahenthiralingameshwar a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT baxbend a28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT morganharry 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT lipkalloydmagdalena 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT warrenannaj 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT hughesnaomi 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT holmesjohn 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT burtonnicolasp 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT mahenthiralingameshwar 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase AT baxbend 28astructureofzoliflodacininadnacleavagecomplexwithstaphylococcusaureusdnagyrase |